DT
HealthMore in Health→
Phase 1 trial points to early promise for IMA401 in solid tumors
Key Takeaways
- IMA401 was tested in 61 patients with advanced solid tumors.
- The maximum tolerated dose was not reached under the trial protocol.
- Researchers set a recommended phase 2 dose of 1 mg to 2 mg every two weeks.
- Common treatment-related side effects included low-grade cytokine release syndrome, lymphopenia, and neutropenia.
DE
DT Editorial Team··via nature.com
